Alert detail
FDA Approval: ENLICITIDE (ENLICITIDE CHLORIDE) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA220848Specialty: CardiologyAdded: 7/23/2026Effective: July 15, 2026federal register
What changed
Oral tablet routes to Part D; no J-code or Part B billing applies.
Who’s affected: Cardiology billing teams · Effective: July 15, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.